-
公开(公告)号：EP2001838B1
公开(公告)日：2014-03-12
申请号：EP07759421.6
申请日：2007-03-27
申请人： Novartis AG , Novartis Pharma GmbH
发明人： PUSATERI, Erin, E. , TOMMASI, Ruben, Alberto , LEUTERT, Thomas , GROB, Jonathan, E. , HONDA, Ayako
IPC分类号： C07C311/19 , C07C311/29 , C07C311/42 , C07C311/46 , C07C311/47 , C07D213/42 , C07D295/12 , A61K31/18 , A61P9/00
CPC分类号： C07C311/19 , C07B2200/09 , C07C311/29 , C07C311/42 , C07C311/46 , C07C311/47 , C07D213/42 , C07D295/13
-
2.发明公开
公开(公告)号：EP3897832A1
公开(公告)日：2021-10-27
申请号：EP19832736.3
申请日：2019-12-13
申请人： Novartis AG
发明人： AZIMIOARA, Mihai , CHEN, Bei , EPPLE, Robert , HARDY, Declan , HONDA, Ayako , LAM, Philip , MALIK, Hasnain Ahmed , MEIER, Fabio , NGUYEN, Truc Ngoc , OKRAM, Barun , PATEL, Sejal , RODRIGUEZ, Rodrigo , SHAW, Duncan , SHEN, Yiping , WU, Baogen
IPC分类号： A61P11/00 , C07D213/73 , C07D213/74 , C07D401/04 , C07D405/14 , C07D413/04 , C07D471/10 , A61K31/4427
-
3.发明公开
公开(公告)号：EP3504194A1
公开(公告)日：2019-07-03
申请号：EP17771589.3
申请日：2017-08-28
申请人： Novartis AG
发明人： PHILLIPS, Dean Paul , AZIMIOARA, Mihai , CHEN, Bei , EPPLE, Robert , NIKULIN, Victor Ivanovich , RODRIGUEZ, Rodrigo A. , PATEL, Sejal , HONDA, Ayako , WU, Baogen , NGUYEN, Truc Ngoc , LAM, Philip , MATHISON, Casey Jacob Nelson , ZHU, Xuefeng , MALIK, Hasnain Ahmed
IPC分类号： C07D401/12 , A61K31/444 , C07D401/14 , A61P11/00
-
公开(公告)号：EP2655340B1
公开(公告)日：2015-01-21
申请号：EP11811150.9
申请日：2011-12-19
申请人： Novartis AG
IPC分类号： C07D239/42 , C07D401/12 , A61K31/505 , A61P35/00
CPC分类号： C07D403/14 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D239/42 , C07D401/12 , C07D401/14 , C07D403/04 , C07D405/14 , C07D413/14 , C07D417/14
-
公开(公告)号：EP2655340A1
公开(公告)日：2013-10-30
申请号：EP11811150.9
申请日：2011-12-19
申请人： Novartis AG
IPC分类号： C07D239/42 , C07D401/12 , A61K31/505 , A61P35/00
CPC分类号： C07D403/14 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D239/42 , C07D401/12 , C07D401/14 , C07D403/04 , C07D405/14 , C07D413/14 , C07D417/14
摘要： The present invention includes novel methods of treating a disease or disorder characterized by hyperactivity of Vps34, and compound as Vps34 inhibitors; particularly compounds of Formula I or a pharmaceutically acceptable salt thereof, as well as methods of treating a disease, disorder, or syndrome associated with Vps34 inhibition, particularly hyperproliferative diseases. The present invention also includes pharmaceutical compositions including compounds of formula I and pharmaceutically acceptable salts thereof.
-
公开(公告)号：EP2001838A2
公开(公告)日：2008-12-17
申请号：EP07759421.6
申请日：2007-03-27
申请人： NOVARTIS AG , Novartis Pharma GmbH
发明人： PUSATERI, Erin, E. , TOMMASI, Ruben, Alberto , LEUTERT, Thomas , GROB, Jonathan, E. , HONDA, Ayako
IPC分类号： C07C311/19 , C07C311/29 , C07C311/42 , C07C311/46 , C07C311/47 , C07D213/42 , C07D295/12 , A61K31/18 , A61P9/00
CPC分类号： C07C311/19 , C07B2200/09 , C07C311/29 , C07C311/42 , C07C311/46 , C07C311/47 , C07D213/42 , C07D295/13
摘要： The present invention provides a compound of formula (I): said compound is inhibitor of MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-9, and/or MMP-12 and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.016 秒)
